A role for single-pill triple therapy in hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 3, 2009, Pages 231-240

  Elijovich, Fernando ^a   Laffer, Cheryl ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Compliance; Drug therapy; Hypertension control rates; Resistant hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACADEMIC ACHIEVEMENT; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; GENERAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; POVERTY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE;

EID: 67449126251     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709334947     Document Type: Review

References (63)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 288: 2981-2997.
2. Amar, J. (2007) Patients with resistant hypertension. J Hypertens 25: S3-S6
3. Andrews, T.C., Ballantyne, C.M., Hsia, J.A. and Kramer, J.H. (2001) Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111: 185-191.
4. Bailey, K.R., Grossardt, B.R. and Graves, J.W. (2008) Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension 51: 841-847.
5. Bakris, G., Hill, M., Mancia, G., Steyn, K., Black, H.R., Pickering, T. et al. (2008) Achieving blood pressure goals globally: Five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens 22: 63-70.
6. Bakris, G.L. and Weir, M.R. (2003) Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 5: 202-209.
7. Beckett, N.S., Peters, R., Fletcher, A.E., Staessen, J.A., Liu, L., Dumitrascu, D. et al. (2008) Treatment of hypertension in patients 80 years of age or older. New Engl J Med 358: 1887-1898.
8. Blood Pressure Lowering Treatment Trialists' Collaboration. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet 362: 1527-1535.
9. Blumenfeld, J.D. and Laragh, J.H. (1998) Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 11: 894-896.
10. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345: 861-869.
11. Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D. et al. (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51: 1403-1419.
12. Chamontin, B., Lang, T., Vaisse, B., Nicodeme, R., Antoine, M.P., Lazorthes, M.L. et al. (2001) Regional management of arterial hypertension in France. Report of a survey of general practitioners [in French]. Arch Mal Coeur Vaiss 94: 823-827.
13. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr, J.L. et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252.
14. Cohn, J.N., Tognoni, G. for the Valsartan Heart Failure Trial Investigators. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 345: 1667-1675.
15. Combination Pharmacotherapy and Public Health Research Working Group. (2005) Combination pharmacotherapy for cardiovascular disease. Ann Intern Med 143: 593-599.
16. Cooperative Research Group. (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 265: 3255-3264.
17. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
18. Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895-906.
19. Destro, M., Luckow, A., Samson, M., Kandra, A. and Brunel, P. (2008) Efficacy and safety of amlodipine / valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens 2: 294-302.
20. Elliott, W.J. (2008) What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens ( Greenwich) 10: 20-26.
21. Gaddam, K.K., Nishizaka, M.K., Pratt-Ubunama, M.N., Pimenta, E., Aban, I., Oparil, S. et al. (2008) Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168: 1159-1164.
22. Gavras, H., Brunner, H.B., Vaughan, E.D. and Laragh, J.H. (1973) Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 180: 1369-1371.
23. Gavras, H., Brunner, H.R., Thurston, H. and Laragh, J.H. (1975) Reciprocation of renin dependency with sodium volume dependency in renal hypertension. Science 188: 1316-1317.
24. Gerbino, P.P. and Shoheiber, O. (2007) Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 64: 1279-1283.
25. Goodfriend, T.L., Ball, D.L. and Gardner, H.W. (2002) An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids 67: 163-167.
26. Gradman, A.H. and Acevedo, C. (2002) Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 4: 343-349.
27. Gu, D., Reynolds, K., Wu, X., Chen, J., Duan, X., Muntner, P. et al. (2002) The International Collaborative Study of Cardiovascular Disease in ASIA: Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 40: 920-927.
28. Hansson, L., Zanchetti, A. and Carruthers, S.G. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762.
29. Harington, M., Kincaid-Smith, P. and McMichael, J. (1959) Results of treatment in malignant hypertension: a seven-year experience in 94 cases. Br Med J 2: 969-980.
30. Hypertension Detection and Follow-up Program Cooperative Group. (1982) The effect of treatment on mortality in ‘mild’ hypertension: results of the hypertension detection and follow-up program. New Engl J Med 307: 976-980.
31. Jamerson, K.A. and Basile, J. (2008) Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich) 10: 40-48.
32. Jamerson, K., Weber, M.A., Bakris, G.L., Dahlöf, B., Pitt, B., Shi, V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med 59: 2417-2428.
33. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031.
34. Klahr, S., Levey, A.S., Beck, G.J., Caggiula, A.W., Hunsicker, L., Kusek, J.W. et al. (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New Engl J Med 330: 877-884.
35. Laffer, C.L. and Elijovich, F. (2002) Essential hypertension of Caribbean Hispanics: sodium, renin, and response to therapy. J Clin Hypertens (Greenwich) 4: 266-273.
36. Laffer, C.L., Gainer, J.V., Waterman, M.R., Capdevila, J.H., Laniado-Schwartzman, M., Nasjletti, A. et al. (2008) The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 51: 767-772.
37. Laffer, C.L., Laniado-Schwartzman, M., Wang, M.H., Nasjletti, A. and Elijovich, F. (2003) Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 107: 574-578.
38. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913.
39. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B. et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 345: 851-860.
40. Ma, Y.H., Schwartzman, M.L. and Roman, R.J. (1994) Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol 267: R579-R589
41. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
42. Motwani, J.G. (2002) Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst 3: 72-78.
43. Neaton, J.D., Grimm Jr, R.H., Prineas, R.J., Stamler, J., Grandits, G.A., Elmer, P.J. et al. (1993) Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. J Am Med Assoc 270: 713-724.
44. Neutel, J.M., Smith, D.H., Silfani, T.N., Lee, Y. and Weber, M.A. (2006) Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 20: 255-262.
45. Okin, P.M., Devereux, R.B., Jern, S., Kjeldsen, S.E., Julius, S., Nieminen, M.S. et al. (2003) Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 108: 684-690.
46. Ong, K.L., Cheung, B.M., Man, Y.B., Lau, C.P. and Lam, K.S. (2007) Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49: 69-75.
47. Packer, M., O'Connor, C.M., Ghali, J.K., Pressler, M.L., Carson, P.E., Belkin, R.N. et al. (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 335: 1107-1114.
48. Payne, K.A. and Esmonde-White, S. (2000) Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2: 515-524.
49. Pfeffer, M.A., Mcmurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med 349: 1893-1906.
50. Philipp, T., Smith, T.R., Glazer, R., Wernsing, M., Yen, J., Jin, J. et al. (2007) Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29: 563-580.
51. Phillips, L.S., Branch, W.T., Cook, C.B., Doyle, J.P., El-Kebbi, I.M., Gallina, D.L. et al. (2001) Clinical inertia. Ann Intern Med 135: 825-834.
52. Sica, D.A. (2002) Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62: 443-462.
53. Staessen, J.A., Thijisq, L., Fagard, R., Celis, H., Birkenhager, W.H., Bulpitt, C.J. et al. (2004) Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22: 847-857.
54. Taylor, A.A. and Shoheiber, O. (2003) Adherence to antihypertensive therapy with fixed-dose amlodipine besylate / benazepril HCl versus comparable component-based therapy. Congest Heart Fail 9: 324-332.
55. Tuomilehto, J., Rastenyte, D., Birkenhager, W.H., Thijs, L., Antikainen, R., Bulpitt, C.J. et al. (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. New Engl J Med 340: 677-684.
56. UK Prospective Diabetes Study Group. (1998 ) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 317: 713-720.
57. Veterans Administration Cooperative Study Group on Antihypertensive Agents. (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. J Am Med Assoc 202: 1028-1034.
58. Veterans Administration Cooperative Study Group on Antihypertensive Agents. (1970) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. J Am Med Assoc 213: 1143-1152.
59. Wald, N.J. and Law, M.R. (2003) A strategy to reduce cardiovascular disease by more than 80%. Br Med J 326: 1419.
60. Weber, M.A., Julius, S., Kjeldsen, S.E., Brunner, H.R., Ekman, S., Hansson, L. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363: 2049-2051.
61. Weinberger, M.H., Fineberg, N.S., Fineberg, S.E. and Weinberger, M. (2001) Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 37: 429-432.
62. Weir, M.R., Gray, J.M., Paster, R. and Saunders, E. (1995) Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 26: 124-130.
63. Wright Jr, J.T., Bakris, G., Greene, T., Agodoa, L.Y., Appel, L.J., Charleston, J. et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 288: 2421-2431.